Paradigm Capital Management Inc. NY Acquires New Stake in Enovis Corporation $ENOV

Paradigm Capital Management Inc. NY bought a new position in Enovis Corporation (NYSE:ENOV) in the second quarter, HoldingsChannel.com reports. The firm bought 1,378,398 shares of the company’s stock, valued at approximately $28,533,000. Enovis accounts for 0.8% of Paradigm Capital Management Inc. NY’s investment portfolio, making the stock its 27th biggest position.

A number of other large investors have also recently added to or reduced their stakes in the company. Arax Advisory Partners acquired a new stake in shares of Enovis in the 4th quarter valued at about $29,000. Allworth Financial LP acquired a new position in shares of Enovis during the second quarter worth about $36,000. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Danske Bank A S bought a new position in shares of Enovis during the third quarter worth about $64,000. Finally, iSAM Funds UK Ltd acquired a new stake in Enovis in the 3rd quarter valued at approximately $80,000. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on ENOV shares. Evercore set a $32.00 target price on Enovis in a research note on Monday, July 6th. Wall Street Zen cut shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group reiterated a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Canaccord Genuity Group cut their price objective on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday, August 17th. Finally, Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.29.

Insider Buying and Selling at Enovis

In related news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $21.62 per share, for a total transaction of $25,944.00. Following the purchase, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. This trade represents a 2.37% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last quarter, insiders purchased 4,200 shares of company stock worth $92,084. 2.90% of the stock is owned by insiders.

Enovis Price Performance

NYSE:ENOV opened at $25.15 on Tuesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. The stock’s 50-day simple moving average is $25.31 and its 200 day simple moving average is $24.19. The company has a market cap of $1.45 billion, a P/E ratio of -1.31 and a beta of 1.34. Enovis Corporation has a 52-week low of $19.14 and a 52-week high of $34.28.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million during the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the prior year, the firm posted $0.79 earnings per share. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts forecast that Enovis Corporation will post 3.15 EPS for the current fiscal year.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.